Last reviewed · How we verify

NCT04684004

Hyperglycemia in Patients With Takotsubo Syndrome

Completed Last updated 28 December 2020
What this trial tests

trial testing To report number of HF events and deaths in Takotsubo Cardiomyopathy in 40 participants. Completed in 1 January 2019.

Timeline
1 January 2013
Primary endpoint
1 January 2017
1 January 2019

Quick facts

Lead sponsorUniversity of Campania Luigi Vanvitelli
StatusCompleted
Study typeOBSERVATIONAL
Enrollment40
Start date1 January 2013
Primary completion1 January 2017
Estimated completion1 January 2019
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

University of Campania Luigi Vanvitelli

Who can join

Adults 18 to 75, any sex, with Takotsubo Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with Takotsubo cardiomiopathy (TTC) have over-inflammation and over-sympathetic tone. However, these conditions could cause higher rate of heart failure (HF) events and deaths at 2 years of follow-up. Conversely, hyperglycemia vs. normoglycemia could result in over expression of inflammatory markers and catecholamines thta could result in higher rate of HF and deaths at 2 years of follow-up in TTC patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Takotsubo Cardiomyopathy

Currently open trials in the same condition.

Other University of Campania Luigi Vanvitelli trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04684004.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing